Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

AstraZeneca

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Employees: 89.9K

Market Cap: $270.3B

Website: http://www.astrazeneca.co.uk

Introduction: AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Clinical Trials

A Study to Investigate the Pharmacokinetics of AZD2389 in Healthy Participants When Administered Alone and in Combination With Quinidine

Phase 1

Recruiting

Conditions: Advanced Chronic Liver Disease
Healthy Participants

Interventions: Drug: AZD2389
Drug: Quinidine

First Posted Date: 2025-05-16

Last Posted Date: 2025-05-23

Lead Sponsor: AstraZeneca

Target Recruit Count: 24

Registration Number: NCT06974565

Locations: 🇺🇸
Research Site, Brooklyn, Maryland, United States

A Study to Investigate How Multiple Oral Doses of AZD2389 Affect the Pharmacokinetics of Midazolam, Caffeine, and Bupropion in Healthy Participants

Phase 1

Active, not recruiting

Conditions: Advanced Chronic Liver Disease
Healthy Participants

Interventions: Drug: AZD2389
Drug: Midazolam
Drug: Caffeine
Drug: Bupropion

First Posted Date: 2025-05-15

Last Posted Date: 2025-06-26

Lead Sponsor: AstraZeneca

Target Recruit Count: 8

Registration Number: NCT06973005

Locations: 🇺🇸
Research Site, Brooklyn, Maryland, United States

ESPERANZA: T-DXd Pan-tumor ECA Study

Not yet recruiting

Conditions: Bladder Cancer
Biliary Tract Cancer
Cervical Cancer
Endometrial Cancer
Ovarian Cancer
Pancreatic Cancer
Colorectal Cancer
Lung Cancer
Other Tumors

First Posted Date: 2025-05-15

Last Posted Date: 2025-05-15

Lead Sponsor: AstraZeneca

Target Recruit Count: 576

Registration Number: NCT06973161

Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)

Phase 3

Recruiting

Conditions: Urinary Bladder Neoplasms
Immune Checkpoint Inhibitors
Methotrexate
Vinblastine
Doxorubicin
Cisplatin
Gemcitabine

Interventions: Drug: Durvalumab
Drug: Methotrexate
Drug: Gemcitabine
Drug: Vinblastine
Drug: Doxorubicin
Drug: Cisplatin

First Posted Date: 2025-05-07

Last Posted Date: 2025-06-25

Lead Sponsor: AstraZeneca

Target Recruit Count: 150

Registration Number: NCT06960577

Locations: 🇪🇸
Research Site, Santiago de Compostela, Spain

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

Phase 3

Not yet recruiting

Conditions: Prostate Cancer

Interventions: Drug: Saruparib
Drug: Placebo
Drug: Androgen Deprivation Therapy (ADT)
Drug: Abiraterone + Prednisolone/Prednisone

First Posted Date: 2025-05-01

Last Posted Date: 2025-05-30

Lead Sponsor: AstraZeneca

Target Recruit Count: 700

Registration Number: NCT06952803

Locations: 🇹🇷
Research Site, Karsiyaka, Turkey

Tezspire Cardiac Events PASS

Not yet recruiting

Conditions: Cardiovascular Events
MACE

Interventions: Drug: Tezepelumab

First Posted Date: 2025-04-30

Last Posted Date: 2025-04-30

Lead Sponsor: AstraZeneca

Target Recruit Count: 95574

Registration Number: NCT06951867

A Study to Investigate the Safety and Pharmacokinetics of Single- and Multiple-ascending Doses of AZD4916 in Healthy Volunteers

Phase 1

Not yet recruiting

Conditions: Healthy Participants

Interventions: Drug: AZD4916
Other: Placebo

First Posted Date: 2025-04-30

Last Posted Date: 2025-04-30

Lead Sponsor: AstraZeneca

Target Recruit Count: 178

Registration Number: NCT06951880

Locations: 🇬🇧
Research Site, Harrow, United Kingdom

Observational Study on the Clinical Profile of Patients With Uncontrolled Severe Asthma Treated With Tezepelumab in Italy

Not yet recruiting

Conditions: Asthma

Interventions: Biological: Tezepelumab

First Posted Date: 2025-04-29

Last Posted Date: 2025-05-30

Lead Sponsor: AstraZeneca

Target Recruit Count: 300

Registration Number: NCT06948396

A Study to Investigate the Effect of AZD5004 on Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and the Effect of Erythromycin on AZD5004 in Healthy Participants

Phase 1

Recruiting

Conditions: Healthy Participants

Interventions: Drug: AZD5004
Drug: Rosuvastatin
Drug: Atorvastatin
Drug: Repaglinide
Drug: Erythromycin
Drug: Simvastatin

First Posted Date: 2025-04-29

Last Posted Date: 2025-05-15

Lead Sponsor: AstraZeneca

Target Recruit Count: 48

Registration Number: NCT06948747

Locations: 🇺🇸
Research Site, Brooklyn, Maryland, United States

A Study to Investigate the Relative Bioavailability of 2 Different Formulations of AZD4144, the Effect of Food and Omeprazole on the Pharmacokinetics of AZD4144 in Healthy Participants

Phase 1

Recruiting

Conditions: Healthy Participants

Interventions: Drug: AZD4144
Drug: Omeprazole

First Posted Date: 2025-04-28

Last Posted Date: 2025-05-28

Lead Sponsor: AstraZeneca

Target Recruit Count: 32

Registration Number: NCT06948006

Locations: 🇬🇧
Research Site, Harrow, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy